

Neuromuscular Effects of Rocuronium Bromide and Mivacurium Chloride Administered Alone and in Combination

Mohamed Naguib, M.B., B.Ch., M.Sc., F.F.A.R.C.S.I., M.D.*

Background: Rocuronium is a new nondepolarizing neuromuscular blocking agent with a rapid onset but with intermediate duration of action. Mivacurium, on the other hand, is a new short-acting nondepolarizing neuromuscular relaxant, but of slower onset of action. The current study was undertaken to characterize the interaction between rocuronium and mivacurium.

Methods: In the first study, the dose-response relations of rocuronium, mivacurium, and their combination were studied in ASA physical status 1 or 2 patients during thiopental-fentanyl-N₂O anesthesia. One hundred ten patients, randomly assigned to 1 of 11 groups of 10 patients each, received mivacurium 30, 50, or 70 $\mu\text{g}\cdot\text{kg}^{-1}$; rocuronium 100, 200, 250, or 300 $\mu\text{g}\cdot\text{kg}^{-1}$; or an equieffective combination of both drugs (1 ED₅₀ rocuronium + 1 ED₅₀ mivacurium; 1/2 ED₅₀ rocuronium + 1/2 ED₅₀ mivacurium; 1/4 ED₅₀ rocuronium + 1/4 ED₅₀ mivacurium; or 1/8 ED₅₀ rocuronium + 1/8 ED₅₀ mivacurium, where ED₅₀ is the dose producing 50% depression of the first twitch height). In the second study, 50 patients, ASA physical status 1 or 2, anesthetized with thiopental-fentanyl-N₂O, were randomly allocated to 5 groups of 10 patients each to receive one of the following neuromuscular blocking drugs or drug combination: rocuronium 600 $\mu\text{g}\cdot\text{kg}^{-1}$ (group 1), mivacurium 150 $\mu\text{g}\cdot\text{kg}^{-1}$ (group 2) rocuronium 150 $\mu\text{g}\cdot\text{kg}^{-1}$ + mivacurium 37.5 $\mu\text{g}\cdot\text{kg}^{-1}$ (group 3), rocuronium 300 $\mu\text{g}\cdot\text{kg}^{-1}$ + mivacurium 75 $\mu\text{g}\cdot\text{kg}^{-1}$ (group 4), or rocuronium 600 $\mu\text{g}\cdot\text{kg}^{-1}$ + mivacurium 150 $\mu\text{g}\cdot\text{kg}^{-1}$ (group 5).

Results: The calculated ED₅₀ values and their 95% confidence intervals were 125 (122-129) and 37 (36-38) $\mu\text{g}\cdot\text{kg}^{-1}$ for the rocuronium and mivacurium groups, respectively. The interaction between rocuronium and mivacurium was found to be synergistic. The measured ED₅₀ of the mixture was only 62% of the predicted value assuming a purely additive interaction. In the second study, rocuronium 600 $\mu\text{g}\cdot\text{kg}^{-1}$ group and group 3 had similar onset times (99 [74-123] and 114 [100-128] s, respectively), which were significantly shorter than that ob-

served in the mivacurium 150 $\mu\text{g}\cdot\text{kg}^{-1}$ group (178 [149-206] s). Onset times in groups 4 and 5 were significantly shorter than that in each of the other study groups (69 [63-76] and 73 [65-80] s, respectively). Clinical duration of action (recovery of T1 to 25% of baseline twitch height) was significantly greater in group 5 (55 [51-60] min) than with all other doses and agents, and briefest ($P < 0.01$) with mivacurium 150 $\mu\text{g}\cdot\text{kg}^{-1}$ (14.5 [12.6-16.5] min) and group 3 (14.7 [13.4-16] min).

Conclusions: The interaction between rocuronium and mivacurium was found to be synergistic. (Key words: Interactions (drug): isobolographic analysis; mivacurium chloride; rocuronium bromide (ORG 9426). Monitoring: train-of-four. Neuromuscular relaxants: mivacurium chloride; rocuronium bromide. Potency: ED₅₀.)

ROCURONIUM bromide (ORG 9426, Organon Teknika, Belgium) and mivacurium chloride are nondepolarizing neuromuscular blocking agents recently introduced to clinical practice.^{1,2} Mivacurium has a considerably shorter duration of action than any other currently used nondepolarizing agent.² Rocuronium, on the other hand, has a brief onset but an intermediate duration of action.¹ These differences in the pharmacodynamic characteristics might confer some advantage in combining the two drugs in clinical practice.

It has been shown that concomitant administration of some mixtures of nondepolarizing neuromuscular blocking compounds (*d*-tubocurarine and gallamine³; pancuronium and gallamine³; or pipecuronium and vecuronium⁴) does result in additive effect. Other combinations of nondepolarizing neuromuscular blocking agents (pancuronium and metocurine^{3,5}; gallamine and metocurine³; or *d*-tubocurarine and pancuronium^{3,5}) clearly demonstrate synergistic effects. Although Waud and Waud⁶ have suggested that potentiation can be entirely of postsynaptic origin, others have attributed synergism to both presynaptic and motor end-plate effects.⁵

The current study was undertaken to characterize the interaction of rocuronium and mivacurium in humans by the isobolographic method and to compare the onset and duration of neuromuscular blockade produced by

* Associate Professor.

Received from the Department of Anaesthesia and the Intensive Care Unit, King Saud University, Faculty of Medicine at King Khalid University Hospital, Riyadh, Saudi Arabia. Accepted for publication April 18, 1994.

Address reprint requests to Dr. Naguib: Department of Anaesthesia, King Khalid University Hospital, P.O. Box 7805, Riyadh 11472, Saudi Arabia.

ROCURONIUM-MIVACURIUM INTERACTIONS

rocuronium and mivacurium in combination with that produced by each drug alone.

Materials and Methods

Interaction Studies

After obtaining institutional approval and informed consent, we studied 110 ASA physical status 1 or 2 patients of both sexes, aged 18–54 (mean 31.7 [SD 8.55]) yr and weighing 45–86 (mean 66.5 [SD 9.5]) kg. All patients were undergoing elective procedures, had no neuromuscular, hepatic or renal disease, and were not taking any drug known or suspected to interfere with neuromuscular function.

All patients received 2 mg oral lorazepam 90 min before operation. An infusion of lactated Ringer's solution was given intravenously before induction of anesthesia. The electrocardiogram, hemoglobin O₂ saturation by pulse oximetry, and arterial blood pressure were monitored. Temperature was monitored by a nasopharyngeal thermistor and maintained at 36.5 ± 0.5°C.

Anesthesia was induced with thiopental 5 mg · kg⁻¹, and was maintained with N₂O and O₂ (70:30) supplemented with fentanyl 4–5 µg · kg⁻¹. The trachea was sprayed with 4 ml of 4% lidocaine and was intubated without the use of neuromuscular relaxants. After intubation, the concentrations of the N₂O, O₂, and CO₂ were determined continuously by a multiple-gas analyzer (Capnomac, Datex Instrumentarium Corporation, Helsinki, Finland). Ventilation was adjusted to maintain normocapnia (end-tidal CO₂ pressure 35–40 mmHg).

The ulnar nerve was stimulated supramaximally at the wrist with square pulses of 0.2-ms duration delivered in a train-of-four (TOF) sequence at 2 Hz every 12 s by a Myotest peripheral nerve stimulator (Biometer International, Odense, Denmark). The resultant contraction of the adductor pollicis muscle was recorded with a force-displacement transducer and neuromuscular function analyzer (Myograph 2000, Biometer International, Odense, Denmark). Preload tension on the thumb was maintained at 300 g throughout the investigation. The first twitch (T1) of the TOF was considered the twitch height.

The following predetermined doses of drugs were administered: mivacurium 30, 50, or 70 µg · kg⁻¹ or rocuronium 100, 200, 250, or 300 µg · kg⁻¹. Studies of the single-drug groups were concluded first, so that doses of combination could be planned. From the dose-

response curves of the neuromuscular agents administered alone, the respective effective doses resulting in a 50% reduction of T1 (ED₅₀) were determined. Subsequently, a dose-response curve was obtained by the administration of the two drugs in a constant dose ratio based on the ED₅₀ values of the single agent. The following dosage combinations were administered (1 ED₅₀ rocuronium + 1 ED₅₀ mivacurium; ½ ED₅₀ rocuronium + ½ ED₅₀ mivacurium; ¼ ED₅₀ rocuronium + ¼ ED₅₀ mivacurium, and ⅛ ED₅₀ rocuronium + ⅛ ED₅₀ mivacurium). From the dose-response curve of the combined drugs, the ED₅₀ value of the total dose of the mixture was calculated, and, based on the known dose ratio, the single doses of the agents in the combination were obtained for plotting on the isobologram. All drugs were administered randomly to subgroups of ten patients, and were injected in 5 s into a rapidly flowing intravenous infusion. In the combination group, drugs were injected simultaneously into two separate intravenous catheters inserted in one arm. The neuromuscular response was recorded as the maximum depression of T1, expressed as a percentage of the control value. Once the maximum effect of the selected dose was reached (that is, when no further decrease in evoked response to three consecutive stimuli occurred), the study was terminated and anesthesia continued as appropriate for surgery.

The percentage values for T1 depression in each group were transformed to probits and plotted against the logarithm of the dose with PCNONLIN version 4.2A (ClinTrials, Lexington, KY).⁷ Regression lines were compared by analysis of covariance. First, we tested the lines to determine if they deviated from parallelism. If they did not, an F test was applied to determine if the elevations were different. If so, a *t* test was applied to determine which line differed in elevation⁸ (BMDP statistical package, release 7.0, University of California Press, Berkeley, CA, 1993). The ED₅₀ and ED₉₅ values (doses causing 50% and 95% depression of twitch tension, respectively) were calculated from the log-probit regression lines for each group. Using analysis of variance, we compared age, body weight, between the different groups. Unless otherwise specified, the results were expressed as means and 95% confidence intervals (CI), and were considered significant when *P* < 0.01.

Isobolographic^{9,10} and algebraic (fractional)¹¹ analyses were used (ED₅₀ level) to define the type of interaction between rocuronium and mivacurium. Isobolographic analysis for drug-drug interaction was conducted according to the procedure of Tallarida *et*

*al.*⁹ This analysis has the advantage of being independent of the slopes of the dose–response curves; *i.e.*, parallelism does not have to be established. The isobologram was constructed by plotting single-drug ED₅₀ points on the dose coordinates of the isobologram, and a combined ED₅₀ point in the dose field. A straight line joining the single-drug ED₅₀ points is termed the “additive line.” If the ED₅₀ of a combination falls on the theoretical additive line, the effect of the drug mixture is additive (zero-interactive). Points to the left of the theoretical additive line would be consistent with a synergistic interaction, whereas points to the right of the line would indicate an antagonistic interaction. CIs for each point were calculated from the variances of each component alone. The CIs were evaluated for statistical significance with a Student’s *t* test.

The algebraic (fractional) analysis was used to describe the magnitude of the interaction. It was based on the expression of the component doses of the two agents of the combination as fractions of the doses that produce the same effect when given separately. The sum of the fractional doses, as expressed by the following equation, indicates the type of interaction:

$$d_r/(ED_{50})_r + d_m/(ED_{50})_m$$

where (ED₅₀)_r and (ED₅₀)_m = the ED₅₀ values of rocuronium and mivacurium, respectively, given alone, and d_r and d_m = the doses of rocuronium and mivacurium, respectively, that when combined are equipotent with (ED₅₀)_r or (ED₅₀)_m. Values near 1 indicate additive interaction, values greater than 1 imply an antagonistic interaction and values less than 1 indicate a synergistic interaction.

Clinical Studies

After obtaining institutional approval and informed consent, 50 ASA physical status 1 or 2 patients of both sexes, aged 21–58 (mean 36 [SD 8.7]) yr and weighing 44–83 (mean 63.4 [SD 9.4]) kg were studied. Premedication and intraoperative monitoring were similar to that described in the isobolographic study. Anesthesia was induced with midazolam 0.03 mg·kg⁻¹, fentanyl 4–5 μg·kg⁻¹, followed by a small dose of thiopental 1–2 mg·kg⁻¹, and maintained with N₂O and O₂ (70:30) supplemented with incremental doses of thiopental to permit baseline TOF monitoring without patient discomfort. Patients were randomly allocated to five groups of 10 each to receive one of the following neuromuscular blocking drug or drug combination: rocuronium 600 μg·kg⁻¹ (approximately 2 ED₉₅) (group

1), mivacurium 150 μg·kg⁻¹ (approximately 2 ED₉₅) (group 2), rocuronium 150 μg·kg⁻¹ + mivacurium 37.5 μg·kg⁻¹ (group 3), rocuronium 300 μg·kg⁻¹ + mivacurium 75 μg·kg⁻¹ (group 4), or rocuronium 600 μg·kg⁻¹ + mivacurium 150 μg·kg⁻¹ (group 5). All drugs were injected in 5 s into a rapidly flowing intravenous infusion. In the combination group, drugs were injected simultaneously into two separate intravenous catheters inserted in one arm. Tracheal intubation was performed at the maximal block. Anesthesia was maintained with N₂O and O₂ (70:30) supplemented with incremental doses of fentanyl and/or thiopental. Additional maintenance doses of mivacurium 100 μg·kg⁻¹ and mixture of rocuronium 150 μg·kg⁻¹ + mivacurium 37.5 μg·kg⁻¹ were administered to all patients in the mivacurium group (group 2) and group 3, respectively. In both groups, the first maintenance dose was administered at T1 = 75% of control. If additional doses were required the second maintenance dose was administered whenever T1 had recovered to 25% of the control. Patients in whom the TOF ratio was less than 0.75 at the completion of the study received neostigmine 30 μg·kg⁻¹ with atropine 15 μg·kg⁻¹ for antagonism of residual neuromuscular blockade.

The times from the injection of neuromuscular blocking drug or drug combination to complete abolition of T1 (onset time), from injection to recovery of T1 to 25% of baseline twitch height (T25) (clinical duration of action), and from recovery of T25 to 75% of baseline twitch height (T75) (recovery index) were recorded. These times were compared with a one-way analysis of variance and the Student-Newman-Keuls multiple-range test. Differences yielding critical values corresponding to *P* < 0.01 were considered statistically significant.

Results

Interaction Studies

The dose–response curves are displayed in figure 1. The slopes for the rocuronium–mivacurium combination, rocuronium and mivacurium groups were 4.01, 4.86 and 6.17, respectively. The regression lines for rocuronium–mivacurium combination and rocuronium groups did not deviate from parallelism, but differed significantly in position. Calculated ED₅₀ and ED₉₅ (and 95% CI) values for rocuronium group were 125 (122–129) and 273 (263–284) μg·kg⁻¹, respectively. Corresponding values for mivacurium group were 37 (36–

ROCURONIUM-MIVACURIUM INTERACTIONS




Fig. 1. Log dose-probit plot for first-twitch depression for rocuronium (squares), mivacurium (circles), and their combination (triangles). Individual points = mean T1 depression (percentage of control) with each dose; bars = 95% confidence intervals. Drug doses are represented as ED_{50} -equivalents.

38) and 69 (66–71) $\mu\text{g} \cdot \text{kg}^{-1}$, respectively. The times for the development of the maximal effect of the smallest dose (mivacurium 30 $\mu\text{g} \cdot \text{kg}^{-1}$ and rocuronium 100 $\mu\text{g} \cdot \text{kg}^{-1}$) and largest dose (mivacurium 70 $\mu\text{g} \cdot \text{kg}^{-1}$ and rocuronium 300 $\mu\text{g} \cdot \text{kg}^{-1}$) were, respectively, 345 (279–393) and 307 (275–339) s for mivacurium and 240 (188–292) and 210 (161–259) s for rocuronium. Corresponding values for their combinations ($\frac{1}{8} ED_{50}$ rocuronium + $\frac{1}{8} ED_{50}$ mivacurium and 1 ED_{50} rocuronium + 1 ED_{50} mivacurium) were 220 (211–269) and 135 (101–169) s, respectively.

The isobolographic analysis demonstrated a synergistic interaction with respect to the neuromuscular blocking activity of rocuronium and mivacurium combination. Figure 2 represents ED_{50} isobologram for the rocuronium–mivacurium interaction. The experimentally determined ED_{50} (and 95% CI) for the combina-

tion was 39 (37–41) $\mu\text{g} \cdot \text{kg}^{-1}$ for rocuronium and 11.5 (11–12) $\mu\text{g} \cdot \text{kg}^{-1}$ for mivacurium. The theoretical additive ED_{50} (and 95% CI) was calculated to be 63 (61–65) $\mu\text{g} \cdot \text{kg}^{-1}$ for rocuronium and 18.5 (18–19) $\mu\text{g} \cdot \text{kg}^{-1}$ for mivacurium. The CIs of these points do not overlap, and the results of a Student's *t* test for potency ratio were significant ($P < 0.0001$) indicating synergism. The fractional (algebraic) analysis of this interaction also demonstrated synergism (table 1).

Clinical Studies

Onset times, clinical duration of action, and recovery indices for all groups are summarized in figure 3 and table 2. Complete neuromuscular blockade developed in all, but 3 patients in group 3 (rocuronium 150 $\mu\text{g} \cdot \text{kg}^{-1}$ + mivacurium 37.5 $\mu\text{g} \cdot \text{kg}^{-1}$), in whom the maximum blockade observed was 99% depression of T1. Patients in group 1 (rocuronium 600 $\mu\text{g} \cdot \text{kg}^{-1}$) and




Fig. 2. First-twitch ED_{50} isobologram for the interaction of rocuronium and mivacurium. Dashed line connecting the single drug ED_{50} points = theoretical additive line; point on line = theoretical additive ED_{50} point (95% confidence interval). The experimentally determined ED_{50} dose (95% confidence interval) of the rocuronium–mivacurium combination fell significantly ($P < 0.0001$) below the corresponding theoretical additive point, indicating synergistic interaction.

Table 1. Rocuronium-Mivacurium Interaction: Equi-effective Doses of Rocuronium-Mivacurium Combination

| Group | Rocuronium Component | | Mivacurium Component | | Sum of Fractions |
|-------------|------------------------------|-----------------------------|------------------------------|-----------------------------|------------------|
| | Fraction of ED ₅₀ | Dose (μg·kg ⁻¹) | Fraction of ED ₅₀ | Dose (μg·kg ⁻¹) | |
| Rocuronium | 1 | 125 | — | — | 1 |
| Mivacurium | — | — | 1 | 37 | 1 |
| Combination | 0.31 | 38.8 | 0.31 | 11.4 | 0.62 |

ED₅₀ = equi-effective dose.

group 3 (rocuronium 150 μg·kg⁻¹ + mivacurium 37.5 μg·kg⁻¹) had similar onset times, which were significantly shorter ($P < 0.01$) than that observed in group 2 (mivacurium 150 μg·kg⁻¹). In groups 4 and 5, onset times were significantly shorter than that in each of the other study groups. Clinical duration of action (recovery to T25) was significantly longer with group 5 than with all other doses and agents, and briefest ($P < 0.01$) with mivacurium 150 μg·kg⁻¹ (group 2) and group 3 (rocuronium 150 μg·kg⁻¹ + mivacurium 37.5 μg·kg⁻¹). The recovery index (recovery from T25 to T75) was significantly less for the mivacurium 150 μg·kg⁻¹ group (group 2), group 3 (rocuronium 150 μg·kg⁻¹ + mivacurium 37.5 μg·kg⁻¹) and group 4 (rocuronium 300 μg·kg⁻¹ + mivacurium 75 μg·kg⁻¹) than that observed with rocuronium group (group 1) and group 5 (rocuronium 600 μg·kg⁻¹ + mivacurium 150 μg·kg⁻¹) (fig. 3 and table 2).

The onset times and the clinical duration of action of the first and the second maintenance doses administered to patients in groups 2 and 3 are presented in table 3.

Discussion

In the current study, isobolographic analysis demonstrated that rocuronium-mivacurium combinations exert a greater effect than that seen with an equipotent dose (in terms of ED₅₀ multiples) of either agent administered alone. The magnitude of this interaction can be appreciated by the examination of the fractional dose scores (table 1). The measured ED₅₀ of the mixture was only 62% of the predicted value assuming a purely additive interaction. The results of this study are consistent with the observation that combinations of structurally dissimilar neuromuscular blocking drugs (pancuronium and *α*-tubocurarine or pancuronium and

metocurine) produce a potentiating response.⁵ The chemical structure of rocuronium bromide (mono-quaternary aminosteroid) is different from that of mivacurium chloride (bis-benzylisoquinolinium compound). On the other hand, a zero (additive) interaction has been demonstrated after administration of chemically related agents such as pipecuronium and vecuronium,⁴ or pancuronium and vecuronium.¹²

The results of this study also demonstrate that combinations of rocuronium and mivacurium produce a shorter onset time and a longer duration of neuromuscular blockade than would be expected from simple additivity. It is interesting to note that the combination administered to the patients in group 3 (rocuronium 150 μg·kg⁻¹ + mivacurium 37.5 μg·kg⁻¹) produced a neuromuscular blockade characterized by rapid onset




Fig. 3. Comparison of the onset time (*top*), duration of action (*middle*), and recovery index (*bottom*) in the different groups. ROC = rocuronium; MIV = mivacurium. Shaded areas = 25th to 75th percentiles; horizontal lines within shaded areas = medians, marking 50th percentiles; rectangular symbols in shaded areas = means; extended bars = ranges.

ROCURONIUM-MIVACURIUM INTERACTIONS

Table 2. Onset and Recovery Data

| | 600 $\mu\text{g} \cdot \text{kg}^{-1}$ Rocuronium (Group 1) | 150 $\mu\text{g} \cdot \text{kg}^{-1}$ Mivacurium (Group 2) | 150 $\mu\text{g} \cdot \text{kg}^{-1}$ Rocuronium + 37.5 $\mu\text{g} \cdot \text{kg}^{-1}$ Mivacurium (Group 3) | 300 $\mu\text{g} \cdot \text{kg}^{-1}$ Rocuronium + 75 $\mu\text{g} \cdot \text{kg}^{-1}$ Mivacurium (Group 4) | 600 $\mu\text{g} \cdot \text{kg}^{-1}$ Rocuronium + 150 $\mu\text{g} \cdot \text{kg}^{-1}$ Mivacurium (Group 5) |
|----------------------|--|--|---|---|--|
| Onset time (s) | 99 (73.7–123)* | 178 (149–206) | 114 (100–128)* | 69 (62.9–75.7)† | 73 (65.1–80.1)† |
| Duration (min) | 36 (28.9–43.5)‡ | 14.5 (12.6–16.5)† | 14.7 (13.4–16)† | 34 (32–36)‡ | 55 (50.6–59.8) |
| Recovery index (min) | 14.8 (10.9–18.9)† | 6.8 (5.4–8.2) | 5.2 (4.3–6) | 7.5 (6.1–8.8) | 11.7 (9.8–13.7)† |

Data are presented as means (95% confidence intervals).

Onset time = the interval between the completion of injection of the neuromuscular blocking drug or drug combination and time to maximal depression T1; Duration = the interval between the completion of injection of the neuromuscular blocking drug or drug combination and time to T1 recovery to 25% of control; recovery index = the time from T25 to T75 percentage of recovery.

* $P < 0.01$ versus 150 $\mu\text{g} \cdot \text{kg}^{-1}$ mivacurium group (group 2).

† $P < 0.01$ versus other groups.

‡ $P < 0.01$ versus 600 $\mu\text{g} \cdot \text{kg}^{-1}$ rocuronium + 150 $\mu\text{g} \cdot \text{kg}^{-1}$ mivacurium combination group (group 5).

(114 s)—similar to that produced by rocuronium 600 $\mu\text{g} \cdot \text{kg}^{-1}$ (group 1)—and short duration (14.7 min)—similar to that produced by mivacurium 150 $\mu\text{g} \cdot \text{kg}^{-1}$ (group 2). Further, combination of rocuronium 300 $\mu\text{g} \cdot \text{kg}^{-1}$ + mivacurium 75 $\mu\text{g} \cdot \text{kg}^{-1}$ (group 4) produced a 30% shorter onset time ($P < 0.01$) than that produced by rocuronium 600 $\mu\text{g} \cdot \text{kg}^{-1}$ (69 vs. 99 s, respectively). The duration of action produced by the latter combination was identical to that produced by rocuronium 600 $\mu\text{g} \cdot \text{kg}^{-1}$ (34 vs. 36.2 min, respectively). Increasing the size of the dose further as in group 5 (rocuronium 600 $\mu\text{g} \cdot \text{kg}^{-1}$ + mivacurium 150 $\mu\text{g} \cdot \text{kg}^{-1}$) did not produce a significantly faster onset time but significantly prolonged the duration of action

(fig. 3 and table 2). A 34% prolongation ($P < 0.01$) of the clinical duration of the latter group was noted when compared with that produced by rocuronium 600 $\mu\text{g} \cdot \text{kg}^{-1}$ (55.2 vs. 36.2 min, respectively).

Several investigators have shown that increasing the dose of nondepolarizing neuromuscular drugs is associated with a reduction in onset time.^{13,14} However, concerns regarding the use of high-dose nondepolarizing neuromuscular relaxants have focused on their prolonged duration of action.^{14,15} Magorian *et al.*¹⁴ noted that doubling the dose of rocuronium from 600 to 1,200 $\mu\text{g} \cdot \text{kg}^{-1}$ was associated not only with 38% reduction ($P < 0.05$) in onset time (89 vs. 55 s), but also with 49% prolongation ($P < 0.05$) in the clinical

Table 3. Onset Times and Clinical Duration of Maintenance Doses

| Group | Maintenance Doses | | | | | |
|---|--|----------------|-------------------------|---|-------------------------|------------------|
| | | First* | | Second† | | |
| | | Onset Time (s) | Clinical Duration (min) | Onset Time (s) | Clinical Duration (min) | |
| 150 $\mu\text{g} \cdot \text{kg}^{-1}$ Mivacurium (group 2) | 100 $\mu\text{g} \cdot \text{kg}^{-1}$ Mivacurium | 120 (104–137) | 12.6 (10.1–15.1) | 100 $\mu\text{g} \cdot \text{kg}^{-1}$ Mivacurium | 64.5 (49.5–79.5) | 13.1 (10.8–15.5) |
| 150 $\mu\text{g} \cdot \text{kg}^{-1}$ Rocuronium + 37.5 $\mu\text{g} \cdot \text{kg}^{-1}$ mivacurium (group 3) | 150 $\mu\text{g} \cdot \text{kg}^{-1}$ Rocuronium + 37.5 $\mu\text{g} \cdot \text{kg}^{-1}$ mivacurium | 50 (44.3–55.5) | 19.6 (17.3–21.9) | 150 $\mu\text{g} \cdot \text{kg}^{-1}$ Rocuronium + 37.5 $\mu\text{g} \cdot \text{kg}^{-1}$ mivacurium | 41 (35.1–46.3) | 20.4 (18.3–22.5) |

Data are presented as means (95% confidence intervals).

Onset time = the time interval between the completion of injection of the neuromuscular blocking drug or drug combination and time to maximal depression T1; Clinical duration = the time interval between the completion of injection of the neuromuscular blocking drug or drug combination and time to T1 recovery to 25% of control.

* First maintenance dose was administered at T1 = 75% of control.

† Second maintenance dose was administered at T1 = 25% of control.

duration of action (37 vs. 73 min). Similarly, Tullock *et al.*¹⁵ reported that the average onset time was reduced from 164 (SEM 27) s to 88 (17) s by increasing the dose of vecuronium from 100 to 300 $\mu\text{g} \cdot \text{kg}^{-1}$. This was accompanied with an increase in the clinical duration (time to T25 recovery) from 42 (5) to 111 (19) min.¹⁵ The same group also noted that increasing the dose of vecuronium further, to 400 $\mu\text{g} \cdot \text{kg}^{-1}$, did not produce a further acceleration in the onset time.¹⁵

The clinical implication of our finding is that by using different combinations of rocuronium and mivacurium, the anesthesiologist can have different mixtures with different characteristics. For example, one mixture (rocuronium 150 $\mu\text{g} \cdot \text{kg}^{-1}$ + mivacurium 37.5 $\mu\text{g} \cdot \text{kg}^{-1}$) is characterized by rapid onset (114 s) and short duration of action (14.7 min), and another mixture (rocuronium 300 $\mu\text{g} \cdot \text{kg}^{-1}$ + mivacurium 75 $\mu\text{g} \cdot \text{kg}^{-1}$) is characterized by a briefer onset time (69 s), but with an intermediate duration (34 min). Therefore, in situations where rapid tracheal intubation is required but succinylcholine is contraindicated, the anesthesiologist can choose between a large dose of a single nondepolarizing neuromuscular blocking agent (with or without a priming dose)¹⁴⁻¹⁶ or, as shown in this study, a combination of smaller doses of rocuronium and mivacurium. An ideal combination for tracheal intubation would reliably reduce the onset time (60 s range), but would not prolong the duration of action. Our results indicate that this can be achieved with the use of rocuronium 300 $\mu\text{g} \cdot \text{kg}^{-1}$ + mivacurium 75 $\mu\text{g} \cdot \text{kg}^{-1}$ combination regimen.

The apparent onset of neuromuscular blockade in the adductor pollicis muscle depends on the pattern and duration of stimulation.¹⁷ Curran *et al.*¹⁷ postulated that TOF (as compared with single-twitch) stimulation at 0.08 Hz hastens onset time by increasing local muscle blood flow. TOF stimulation every 12 s was used in the current study. A similar stimulus pattern (TOF every 10–15 s) was used by other investigators for determination of the dose–response relations of mivacurium.^{18,19} Because the same pattern of stimulation was used for all patients, the relative potencies of mivacurium and rocuronium determined in this study are likely to be accurate.

The ED₅₀ value of 37 (95% CI 36–38) $\mu\text{g} \cdot \text{kg}^{-1}$ for mivacurium calculated in the current study is in close agreement with (39 and 41 $\mu\text{g} \cdot \text{kg}^{-1}$) that reported by Caldwell *et al.*¹⁸ and Weber *et al.*,¹⁹ respectively, who used TOF mode of stimulation and mechanomyography during thiopental–fentanyl–N₂O anesthesia. In this

study, the calculated first-twitch ED₅₀ (and 95% CI) value for rocuronium during thiopental–fentanyl–N₂O anesthesia was 125 (122–129) $\mu\text{g} \cdot \text{kg}^{-1}$. Similar ED₅₀ values were reported by Cooper *et al.*²⁰ (147 (95% CI 130–165) $\mu\text{g} \cdot \text{kg}^{-1}$) who used single-twitch mode of stimulation and mechanomyography.

The isobolographic method is a generally valid procedure for analyzing interactions between agents irrespective of their mechanisms of action or their dose–response relations.^{9,10} In addition, in isobolographic analysis, it is unnecessary to have complete dose–response curves of all of the agents in a combination to detect and categorize an interaction.¹⁰ Chou and Talalay²¹ indicated, however, that this method of analysis can be used to demonstrate synergism when the effect of drugs are “mutually exclusive”—that is, when they act at (or are bound by) the same receptor or enzyme site.

Although the precise mechanisms underlying synergistic interaction are not known, hypotheses that have been put forward include (1) the existence of multiple binding sites at the neuromuscular junction (pre- and postsynaptic receptors)^{5,22,23}; (2) nonequivalence of binding sites in the regions of the α -chain responsible for ligand recognition, resulting from the asymmetric azimuthal orientation of the five subunits in the acetylcholine pentamer that determines different contacts for the α_1 and α_2 chains^{6,24,25}; and (3) alteration of the pharmacokinetic behavior of one drug by the other, a hypothesis disputed by Martyn *et al.*²⁶

In conclusion, both isobolographic and clinical studies demonstrated that the interaction of rocuronium and mivacurium combination is the result of synergistic action at the neuromuscular junction. Different combinations yielded different clinical profiles. One mixture (rocuronium 150 $\mu\text{g} \cdot \text{kg}^{-1}$ + mivacurium 37.5 $\mu\text{g} \cdot \text{kg}^{-1}$) was characterized by rapid onset (114 s) and short duration of action (14.7 min), and another (rocuronium 300 $\mu\text{g} \cdot \text{kg}^{-1}$ + mivacurium 75 $\mu\text{g} \cdot \text{kg}^{-1}$) was characterized by a briefer onset time (69 s), but with an intermediate clinical duration (34 min). Increasing the size of the dose in the mixture to (rocuronium 600 $\mu\text{g} \cdot \text{kg}^{-1}$ + mivacurium 150 $\mu\text{g} \cdot \text{kg}^{-1}$) did not affect onset time significantly but resulted in a significant prolongation of the duration of action.

References

1. Wierda JMKH, De Wit APM, Kuizenga K, Agoston S: Clinical observations on the neuromuscular blocking action of ORG 9426,

ROCURONIUM-MIVACURIUM INTERACTIONS

- a new steroidal non-depolarizing agent. *Br J Anaesth* 64:521-523, 1990
2. Savarese JJ, Ali HH, Basta SJ, Embree PB, Scott RPF, Sunder N, Weakly JN, Wastila WB, El-Sayad HA: The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U), a short-acting nondepolarizing ester neuromuscular blocking drug. *ANESTHESIOLOGY* 68:723-732, 1988
 3. Waud BE, Waud DR: Quantitative examination of the interaction of competitive neuromuscular blocking agents on the indirectly elicited twitch. *ANESTHESIOLOGY* 61:420-427, 1984
 4. Naguib M, Abdulatif M: Isobolographic and dose-response analysis of the interaction between pipecuronium and vecuronium in surgical patients. *Br J Anaesth* 71:556-560, 1993
 5. Lebowitz PW, Ramsey FM, Savarese JJ, Ali HH: Potentiation of neuromuscular blockade in man produced by combinations of pancuronium and metocurine or pancuronium and d-tubocurarine. *Anesth Analg* 59:604-609, 1980
 6. Waud BE, Waud DR: Interaction among agents that block end-plate depolarization competitively. *ANESTHESIOLOGY* 63:4-15, 1985
 7. Statistical Consultants: PCNONLIN and NONLIN84: Software for the statistical analysis on nonlinear models. *Am Stat* 40:52, 1986
 8. Finney DJ: *Statistical Methods in Biological Assays*. 2nd edition. London, Griffin, 1971, pp 21-57
 9. Tallarida RJ, Porreca F, Cowan A: Statistical analysis of drug-drug and site-site interactions with isobolograms. *Life Sci* 45:947-961, 1989
 10. Berenbaum MC: What is synergy? *Pharmacol Rev* 41:93-141, 1989
 11. Berenbaum MC: Synergy, additivism and antagonism in immunosuppression. *J Clin Exp Immunol* 28:1-18, 1977
 12. Ferres CJ, Mirakhor RK, Pandit SK, Clarke RSJ, Gibson FM: Dose-response studies with pancuronium, vecuronium and their combination. *Br J Clin Pharmacol* 18:947-950, 1984
 13. Healy TEJ, Pugh ND, Kay B, Sivalingam T, Petts HV: Atracurium and vecuronium: Effect of dose on the time of onset. *Br J Anaesth* 58:620-624, 1986
 14. Magorian T, Flannery KB, Miller RD: Comparison of rocuronium, succinylcholine, and vecuronium for rapid-sequence induction of anesthesia in adult patients. *ANESTHESIOLOGY* 79:913-918, 1993
 15. Tullock WC, Diana P, Cook R, Wiks DH, Brandom BW, Stiller RL, Beach CA: Neuromuscular and cardiovascular effects of high-dose vecuronium. *Anesth Analg* 70:86-90, 1990
 16. Naguib M, Abdulatif M, Gyasi HK, Absood GH: Priming with atracurium: Improving intubating conditions with additional doses of thiopental. *Anesth Analg* 65:1295-1299, 1986
 17. Curran MJ, Donati F, Bevan DR: Onset and recovery of atracurium and suxamethonium-induced neuromuscular blockade with simultaneous train-of-four and single twitch stimulation. *Br J Anaesth* 59:989-994, 1987
 18. Caldwell JE, Kitts JB, Heier T, Fahey MR, Lynam DP, Miller RD: The dose-response relationships of mivacurium chloride in humans during nitrous oxide-fentanyl or nitrous oxide-enflurane anesthesia. *ANESTHESIOLOGY* 70:31-35, 1989
 19. Weber S, Brandom BW, Powers DM, Sarner JB, Woelfel SK, Cook RD, Foster VJ, McNulty BF, Weakly JN: Mivacurium chloride (BW B1090U)-induced neuromuscular blockade during nitrous oxide-isoflurane and nitrous oxide-narcotic anesthesia in adult surgical patients. *Anesth Analg* 67:495-499, 1988
 20. Cooper RA, Mirakhor RK, Elliott P, McCarthy GJ: Estimation of the potency of ORG 9426 using different modes of nerve stimulation. *Can J Anaesth* 39:139-142, 1992
 21. Chou T-C, Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. *Adv Enzyme Reg* 22:27-55, 1983
 22. Pollard BJ, Jones RM: Interactions between tubocurarine, pancuronium and alcuronium demonstrated in the rat phrenic nerve-hemidiaphragm preparation. *Br J Anaesth* 55:1127-1130, 1983
 23. Bowman WC, Prior C, Marshall IG: Presynaptic receptors in the neuromuscular junction. *Ann NY Acad Sci* 604:69-81, 1990
 24. Yu XM, Hall ZW: Extracellular domains mediating ϵ subunit interactions of muscle acetylcholine receptor. *Nature* 352:64-67, 1991
 25. Sine SM: Molecular dissection of subunit interfaces in acetylcholine receptor: Identification of residues that determine curare selectivity. *Proc Natl Acad Sci USA* 90:9436-9440, 1993
 26. Martyn JAJ, Leibel WS, Matteo RS: Competitive nonspecific binding does not explain the potentiating effects of muscle relaxants combinations. *Anesth Analg* 62:160-163, 1983